Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MDM4 | O15151 | 3/20 | 0.51 |
| ▸ | TP53 | P04637 | 3/20 | 0.51 |
| ▸ | SLC17A5 | Q9NRA2 | 1/20 | 0.47 |
| ▸ | MDM2 | Q00987 | 5/20 | 0.47 |
| ▸ | CASP3 | P42574 | 2/20 | 0.46 |
| ▸ | ITGB2 | P05107 | 1/20 | 0.44 |
| ▸ | ICAM1 | P05362 | 1/20 | 0.44 |
| ▸ | ITGAL | P20701 | 1/20 | 0.44 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.43 |
| ▸ | TLR2 | O60603 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30951920 | 1.00 | MDM4 (0.51) | MDM4TP53SLC17A5MDM2CASP3 | |
| SCHEMBL30951921 | 1.00 | MDM4 (0.51) | MDM4TP53SLC17A5MDM2CASP3 | |
| SCHEMBL29907877 | 0.92 | MDM4 (0.51) | MDM4TP53SLC17A5MDM2CASP3 | |
| SCHEMBL30532481 | 0.92 | MDM4 (0.51) | MDM4TP53SLC17A5MDM2CASP3 | |
| SCHEMBL120613 | 0.92 | MDM4 (0.51) | MDM4TP53SLC17A5MDM2CASP3 | |
| SCHEMBL29928500 | 0.92 | MDM4 (0.51) | MDM4TP53SLC17A5MDM2CASP3 | |
| SCHEMBL120601 | 0.92 | MDM4 (0.51) | MDM4TP53SLC17A5MDM2CASP3 | |
| SCHEMBL29872206 | 0.92 | MDM4 (0.51) | MDM4TP53SLC17A5MDM2CASP3 | |
| SCHEMBL2305506 | 0.92 | MDM4 (0.51) | MDM4TP53SLC17A5MDM2CASP3 | |
| SCHEMBL30819571 | 0.91 | MDM4 (0.52) | MDM4TP53SLC17A5MDM2CASP3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240218021-A1 | CYCLIN INHIBITORS | CIRCLE PHARMA, INC. | 2024-07-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240218021-A1 | CYCLIN INHIBITORS | CCNI, CCNC, CDK2 | MDM4 1200/4885TP53 88/4885SLC17A5 4378/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.